Insulin/IGF-1 hybrid receptor expression on human platelets: Consequences for the effect of insulin on platelet function

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 12, 2009, Pages 2123-2130

  Hunter, R W ^a   Hers, I ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Akt; Hybrid receptor; IGF 1; Insulin; PKB; Platelets

Indexed keywords

FIBRINOGEN; INSULIN; INSULIN RECEPTOR; MESSENGER RNA; PROTEIN SUBUNIT; SOMATOMEDIN C RECEPTOR;

ARTICLE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DIMERIZATION; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

BLOOD PLATELETS; CELLS, CULTURED; DIMERIZATION; FIBRINOGEN; HUMANS; INSULIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PROTEIN SUBUNITS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RNA, MESSENGER;

EID: 77449091982     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03637.x     Document Type: Article

References (24)

1. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-23.
2. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 2008; 5: 138-44.
3. Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H. Cardiovascular disease and insulin-like growth factor I. Circulation 2002; 106: 893-5.
4. Siddle K, Urso B, Niesler CA, Cope DL, Molina L, Surinya KH, Soos MA. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001; 29: 513-25.
5. Treadway JL, Morrison BD, Goldfine ID, Pessin JE. Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro. J Biol Chem 1989; 264: 21450-3.
6. Benyoucef S, Surinya KH, Hadaschik D, Siddle K. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem J 2007; 403: 603-13.
7. Ferreira IA, Mocking AI, Feijge MA, Gorter G, Van Haeften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26: 417-22.
8. Anfossi G, Russo I, Trovati M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr Diabetes Rev 2006; 2: 409-30.
9. Westerbacka J, Yki-Jarvinen H, Turpeinen A, Rissanen A, Vehkavaara S, Syrjala M, Lassila R. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 167-72.
10. Rauchfuss S, Geiger J, Walter U, Renne T, Gambaryan S. Insulin inhibition of platelet-endothelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets. J Thromb Haemost 2008; 6: 856-64.
11. Motani AS, Anggard EE, Ferns GA. Recombinant insulin-like growth factor-1 modulates aggregation in human platelets via extracellular calcium. Life Sci 1996; 58: PL269-74.
12. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway. Blood 2007; 110: 4243-52.
13. Hunter RW, Harper MT, Hers I. The PKB inhibitor Akti-1/2 potentiates PAR-1-mediated platelet function independently of its ability to block PKB. J Thromb Haemost 2008; 6: 1923-32.
14. Hunter RW, Mackintosh C, Hers I. Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem 2009; 284: 12339-48.
15. Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol 1996; 93: 204-14.
16. Ferreira IA, Eybrechts KL, Mocking AI, Kroner C, Akkerman JW. IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004; 279: 3254-64.
17. Gambaryan S, Geiger J, Renne T, Walter U. Inhibition of platelets by insulin? A reply to a rebuttal letter. J Thromb Haemost 2009; 7: 371-3.
18. Akkerman JW, Gerrits AJ, Ferreira IA, Heemskerk JW. Insulin inhibition of platelet-endothelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets: a rebuttal. J Thromb Haemost 2009; 7: 369-71; author reply 71-3.
19. Hartmann K, Baier TG, Loibl R, Schmitt A, Schonberg D. Demonstration of type I insulin-like growth factor receptors on human platelets. J Recept Res 1989; 9: 181-98.
20. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 1993; 290(Pt 2): 419-26.
21. Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, Busse R. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 2003; 90: 863-71.
22. Hajek AS, Joist JH, Baker RK, Jarett L, Daughaday WH. Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest 1979; 63: 1060-5.
23. Tamura H, Ogata K, Luo S, Nakamura K, Yokose N, Dan K, Tohyama K, Yoshida Y, Hamaguchi H, Sakamaki H, Kuwaki T, Tahara T, Kato T, Nomura T. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol 1998; 103: 778-84.
24. Arnqvist HJ. The role of IGF-system in vascular insulin resistance. Horm Metab Res 2008; 40: 588-92.